💉For the first time in 50 years there is a new treatment that helps improve the management of asthma and chronic obstructive pulmonary disease attacks! @UWAresearch@Resp_Health@SanjayResp
https://t.co/8CLXBRb0LQ
@ConversationUK invited us to talk about ABRA. Thank you for highlighting this huge development in asthma and COPD attack treatment. Check it out 👇🏾
@MonaBafadhel@russell_doc
https://t.co/KGj3bXZ4Tj
Breaking News! 🎉 A major breakthrough in asthma treatment! 🫁 A trial managed by @OxfordRespTrial has discovered the first new treatment for asthma attacks in 50 years. This could revolutionize care for millions. @UniofOxford@NDMOxford#research https://t.co/ImdJFtw6Gz
Such an important study. In people with acute asthma and COPD with eosinophilia regimes containing benralizumab were superior to prednisone alone in reference treatment failure at 90 days
A new era in the treatment of acute exacerbations of #asthma and #COPD - The ABRA Trial. Clarus Leung and I highlight ABRA's importance as well as its limitations.
https://t.co/JL6SUTbM0f
Asthma & COPD breakthrough! For 1st time in 50 yrs, a new treatment's been found. Dr Sanjay Ramakrishnan's (@SanjayResp) trial shows benralizumab injection reduces severe asthma & COPD attacks. https://t.co/43iNdExyG3
#AsthmaTreatment#COPD#RespiratoryHealth
Treating eosinophilic exacerbations of #asthma and #COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial
Read open access here: https://t.co/WJ9R052uiF
@MonaBafadhel @BTSrespiratory @SanjayResp@kingsmedicine
@guardian@BBCWorld highlighting the patient impact of the ABRA trial. Thank you to Alison and Geoff for their amazing support of this study
https://t.co/rDpW3NsuBA
Wow. ABRA was highlighted by @EricTopol Thank you!
So proud to see this out for everyone to read. Our patients with and asthma and COPD deserve the best.
@LancetRespirMed@MonaBafadhel
Some very good news for people with asthma and COPD.
The first new treatment for acute attacks in over 50 years—a monoclonal antibody vs interleukin-5 receptor-α—with efficacy in a randomized trial
https://t.co/YW3PbKz0DF @LancetRespirMed@SanjayResp@MonaBafadhel@kingsmedicine
Today is #worldCODPday, started by @gold_copd. This years theme is "Know Your Lung Function" as #spirometry is important for diagnosis & monitoring lung health.
TSANZ members worked with @ACSQHC to develop the recent clinical standards on COPD.
https://t.co/EyJ6fViHr6
Are you a bronchiectasis nerd? Want to come live in a city with the best beaches in the world? Look no further. This is your dream job opportunity! @NMHS_WA
The @Resp_Health infrastructure will allow you to grow your research too! @tsanz_thoracic @BTSrespiratory @EuroRespSoc
🚨JOB OPPORTUNITY
@Charlies_Resp is looking for a new colleague with a sub specialist interest in CF and non-CF bronchiectasis. Come lead the state CF service. You will get to work at our collaborative unit with our amazing multi-professional team.
Ad 👇
https://t.co/eyQ1g0BV0p